#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	5214	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2234	282.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1824	1824	T	322	T,G	321,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	5214	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2234	282.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1558	1558	C	367	C	367	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	9062	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4000	282.6	0	.	n	.	0	C543T	SNP	543	543	C	1158	1158	T	335	T,C	334,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	9062	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4000	282.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1952	1952	A	367	A	367	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	9062	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4000	282.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2586	2586	C	348	C,G	347,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	9062	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4000	282.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2660	2660	A	307	A	307	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	9062	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4000	282.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3212	3212	C	343	C	343	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	822	folP	855	855	99.88	folP.l15.c4.ctg.1	1887	54.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1207	1209	AGC	65;65;65	A;G;C	65;65;65	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1968	gyrA	2751	2751	99.82	gyrA.l15.c17.ctg.1	3895	63.0	0	.	p	.	0	V290I	NONSYN	868	870	GTT	1470	1472	ATT	82;81;82	A;T;T	82;81;82	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1968	gyrA	2751	2751	99.82	gyrA.l15.c17.ctg.1	3895	63.0	1	SNP	p	S91F	0	.	.	271	273	TCC	873	875	TCC	77;77;77	T;C;C	77;77;77	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1968	gyrA	2751	2751	99.82	gyrA.l15.c17.ctg.1	3895	63.0	1	SNP	p	D95G	0	.	.	283	285	GAC	885	887	GAC	78;79;77	G;A;C	78;79;77	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1968	gyrA	2751	2751	99.82	gyrA.l15.c17.ctg.1	3895	63.0	1	SNP	p	D95N	0	.	.	283	285	GAC	885	887	GAC	78;79;77	G;A;C	78;79;77	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	800	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1742	57.0	1	SNP	p	G45D	1	.	.	133	135	GAC	621	623	GAC	101;101;100	G;A,G;C	101;100,1;100	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	438	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1461	37.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	1872	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3497	66.7	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1737	1739	ATC	116;110;105	A;T;C	116;109;104	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	1872	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3497	66.7	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1890	1892	GCA	88;89;92	G;C;A	88;89;92	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	1872	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3497	66.7	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2373	2375	ATT	76;77;77	A;T;T,A,G	76;77;75,1,1	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	1872	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3497	66.7	1	SNP	p	D86N	0	.	.	256	258	GAC	843	845	GAC	80;79;78	G;A;C,T	80;79;77,1	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	1872	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3497	66.7	1	SNP	p	S87W	0	.	.	259	261	AGT	846	848	AGT	79;80;80	A;G;T,G	79;80;79,1	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	1872	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3497	66.7	1	SNP	p	S87I	0	.	.	259	261	AGT	846	848	AGT	79;80;80	A;G;T,G	79;80;79,1	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	1872	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3497	66.7	1	SNP	p	S87R	0	.	.	259	261	AGT	846	848	AGT	79;80;80	A;G;T,G	79;80;79,1	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	1872	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3497	66.7	1	SNP	p	S88P	0	.	.	262	264	TCC	849	851	TCC	83;83;83	T;C,G;C	83;82,1;83	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1482	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3140	58.8	0	.	p	.	0	H611N	NONSYN	1831	1833	CAC	2462	2464	AAC	71;70;70	A;A;C	71;70;70	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1482	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3140	58.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1859	1861	GGC	87;87;87	G,C;G;C	86,1;87;87	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	0	.	p	.	0	A438V	NONSYN	1312	1314	GCA	1912	1914	GTC	117;116;116	G;T;C	117;116;116	.	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	0	.	p	.	0	V444E	NONSYN	1330	1332	GTT	1930	1932	GAA	111;110;113	G;A;A	111;110;113	.	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	0	.	p	.	0	L448V	NONSYN	1342	1344	CTC	1942	1944	GTC	111;109;111	G;T;C	111;109;111	.	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	0	.	p	.	0	Q458K	NONSYN	1372	1374	CAA	1972	1974	AAA	109;107;106	A;A;A	109;107;106	.	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	0	.	p	.	0	I462V	NONSYN	1384	1386	ATA	1984	1986	GTC	102;103;105	G;T;C,T	102;103;104,1	.	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	0	.	p	.	0	F463I	NONSYN	1387	1389	TTC	1987	1989	ATC	105;105;103	A;T;C	105;105;103	.	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	0	.	p	.	0	E465A	NONSYN	1393	1395	GAA	1993	1995	GCC	100;100;99	G;C;C	100;100;99	.	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	0	.	p	.	0	R469K	NONSYN	1405	1407	CGC	2005	2007	AAA	99;97;97	A,C;A;A	98,1;97;97	.	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	0	.	p	.	0	E470K	NONSYN	1408	1410	GAG	2008	2010	AAA	97;99;100	A;A;A	97;99;100	.	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	0	.	p	.	0	N473E	NONSYN	1417	1419	AAT	2017	2019	GAG	103;101;101	G;A;G	103;101;101	.	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	0	.	p	.	0	N513Y	NONSYN	1537	1539	AAC	2137	2139	TAC	71;71;70	T;A;C	71;71;70	.	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	0	.	p	.	0	G517A	NONSYN	1549	1551	GGT	2149	2151	GCC	79;79;79	G;C;C	79;79;79	.	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	0	.	p	.	0	A550T	NONSYN	1648	1650	GCA	2248	2250	ACA	89;88;88	A;C;A	89;88;88	.	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1531	1533	GCA	112;111;111	G;C;A,G	112;111;110,1	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1534	1536	ATC	112;113;110	A;T;C,T	112;113;109,1	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1546	1548	GTG	113;112;110	G;T;G	113;112;110	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1546	1548	GTG	113;112;110	G;T;G	113;112;110	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2104	2106	GCG	78;78;79	G;C;G	78;78;79	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2104	2106	GCG	78;78;79	G;C;G	78;78;79	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2227	2229	GGT	90;90;90	G;G;T	90;90;90	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2236	2238	GGC	88;88;89	G;G;C	88;88;89	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	539	1578	penA	1752	1752	95.66	penA.l6.c4.ctg.1	2905	67.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2254	2256	CCG	92;92;92	C;C;G	92;92;92	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	2174	ponA	2397	2397	99.96	ponA.l6.c17.ctg.1	3501	77.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	962	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2302	52.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	874	874	C	69	C	69	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	158	porB1a	984	152	93.42	porB1a.l15.c17.ctg.2	154	24.4	0	.	p	.	0	V258L	NONSYN	772	774	GTA	12	14	TTA	8;8;9	T;T;A	8;8;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	158	porB1a	984	152	93.42	porB1a.l15.c17.ctg.2	154	24.4	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	57	59	CAT	30;30;30	C;A;T	30;30;30	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	158	porB1a	984	152	93.42	porB1a.l15.c17.ctg.2	154	24.4	0	.	p	.	0	D274S	NONSYN	820	822	GAT	60	62	AGT	30;30;30	A;G;T	30;30;30	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	158	porB1a	984	152	93.42	porB1a.l15.c17.ctg.2	154	24.4	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	69	71	TAC	30;30;30	T;A;C	30;30;30	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1210	porB1b	1035	1035	98.75	porB1b.l6.c4.ctg.1	2173	69.4	0	.	p	.	0	R143G	NONSYN	427	429	AGA	920	922	GGA	101;102;102	G;G;A,C	101;102;101,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1210	porB1b	1035	1035	98.75	porB1b.l6.c4.ctg.1	2173	69.4	0	.	p	.	0	.	INDELS	629	630	AA	1123	1125	TAG	92;91;90	T;A;G	92;91;90	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1210	porB1b	1035	1035	98.75	porB1b.l6.c4.ctg.1	2173	69.4	0	.	p	.	0	.	MULTIPLE	631	633	TAC	1127	1130	CAAT	90;89;88;87	C;A;A,T;T	90;89;87,1;87	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1210	porB1b	1035	1035	98.75	porB1b.l6.c4.ctg.1	2173	69.4	0	.	p	.	0	N212fs	FSHIFT	634	634	A	1132	1132	T	87	T	87	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1210	porB1b	1035	1035	98.75	porB1b.l6.c4.ctg.1	2173	69.4	1	SNP	p	G120K	0	.	.	358	360	GGT	851	853	GGT	102;102;101	G,A;G;T	100,1;101;100	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1210	porB1b	1035	1035	98.75	porB1b.l6.c4.ctg.1	2173	69.4	1	SNP	p	A121N	0	.	.	361	363	GCC	854	856	GCC	103;101;100	G;C,T;C	102;99,1;99	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	1210	porB1b	1035	1035	98.75	porB1b.l6.c4.ctg.1	2173	69.4	1	SNP	p	A121D	0	.	.	361	363	GCC	854	856	GCC	103;101;100	G;C,T;C	102;99,1;99	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	3810	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5410	87.9	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2240	2242	CAT	116;114;114	C;A,C;T	116;113,1;114	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	558	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1406	49.5	1	SNP	p	V57M	0	.	.	169	171	GTG	759	761	GTG	109;109;107	G,T;T;G	108,1;109;107	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
